12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ZS-9: Phase III data

Top-line data from the double-blind, U.S. and Australian Phase III ZS-003 trial in 753 patients with mild to moderate hyperkalemia, defined as potassium levels of 5-6.5 mEq/L, showed that the 2.5, 5 and 10 g doses of oral ZS-9 given thrice daily for the first 48 hours (acute phase) each met the primary endpoint of reducing serum potassium levels from baseline to 48 hours vs. placebo (p=0.0009, p<0.0001 and p<0.0001, respectively). The 1.25 g...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >